Mechanism of retinoblastoma tumor cell death after focal chemotherapy, radiation, and vascular targeting therapy in a mouse model

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 12, 2007, Pages 5371-5376

  Jockovich, Maria Elena ^a   Suarez, Fernando ^a   Alegret, Armando ^a   Piña, Yolanda ^a   Hayden, Brandy ^a   Cebulla, Colleen ^a   Feuer, William ^a   Murray, Timothy G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANECORTAVE; CARBOPLATIN; CASPASE 3; COMBRETASTATIN A4; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; COMBRETASTATIN A 4; COMBRETASTATIN A-4; PREGNANE DERIVATIVE; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; EXTERNAL BEAM RADIOTHERAPY; HISTOPATHOLOGY; IMMUNOFLUORESCENCE TEST; MOUSE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RETINOBLASTOMA; TREATMENT OUTCOME; TUMOR VASCULARIZATION; ANIMAL; COMPUTER ASSISTED RADIOTHERAPY; DISEASE MODEL; DRUG EFFECT; METABOLISM; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RADIATION EXPOSURE; RETINA TUMOR; TIME; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOPLATIN; CASPASE 3; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; IN SITU NICK-END LABELING; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PREGNADIENEDIOLS; RADIOTHERAPY, CONFORMAL; RETINAL NEOPLASMS; RETINOBLASTOMA; STILBENES; TIME FACTORS;

EID: 38549144763     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.07-0708     Document Type: Article

References (32)

1. Tamboli A, Podgor MJ, Horm JW. The incidence of retinoblastoma in the United States: 1974 through 1985. Archiv Ophthalmol. 1990;108:128-132.
2. Sant M, Capocaccia R, Badioni V. Survival for retinoblastoma in Europe. Eur J Cancer. 2001;37:730-735.
3. Novakovic B. U.S. childhood cancer survival, 1973-1987. Med Pediatr Oncol. 1994;23:480-486.
4. Tatlipinar S, Soylemezoglu F, Kiratli H, Bilgic S. Quantitative analysis of apoptosis in retinoblastoma. Clin Exp Ophthalmol. 2002;30:131-135.
5. Madigan MC, Penfold PL. Human retinoblastoma: a morphological study of apoptotic, leukocytic, and vascular elements. Ultrastructural Pathol. 1997;21:95-107.
6. Kim CJ, Chi JG, Choi HS, et al. Proliferation not apoptosis as a prognostic indicator in retinoblastoma. Virchows Arch. 1999;434:301-305.
7. Cha SC, Suh KS, Song KS, Lim K. Cell death in retinoblastoma: electron microscopic, immunohistochemical, and DNA fragmentation studies. Ultrastructural Pathol. 2000;24:23-32.
8. Kerimogglu H, Kiratli H, Dincturk AA, Soylemezoglu F, Bilgic S. Quantitative analysis of proliferation, apoptosis, and angiogenesis in retinoblastoma and their association with the clinicopathologic parameters. Jpn J Ophthalmol. 2003;47:565-571.
9. Chong EM, Coffee RE, Chintagumpala M, Hurwitz RL, Hurwitz MY, Chevez-Barrios P, Extensively necrotic retinoblastoma is associated with high-risk prognostic factors. Arch Pathol Lab Med. 2006;130:1669-1672.
10. Bartova E, Kozubek S, Gajova H, et al. Cytogenetics and cytology of retinoblastomas. J Cancer Res Clin Oncol. 2003;129:89-99.
11. Giuliano M, Lauricella M, Vassallo E, Carabillo M, Vento R, Tesoriere G. Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors. Invest Ophthalmol Vis Sci. 1998;39:1300-1311.
12. Vento R, Giuliano M, Lauricella M, Carabillo M, Di Liberto D, Tesoriere G. Induction of programmed cell death in human retinoblastoma Y79 cells by C2-ceramide. Mol Cell Biochem. 1998;185:7-15.
13. Lauricella M, Giuliano M, Emanuele S, Vento R, Tesoriere G. Apoptotic effects of different drugs on cultured retinoblastoma Y79 cells. Tumour Biol. 1998;19:356-363.
14. Cullinan AE, Brandt CR. Cytokine induced apoptosis in human retinoblastoma cells. Mol Vis. 2004;10:315-322.
15. Fukasawa Y, Ishikura H, Takada A, et al. Massive apoptosis in infantile myonbromatosis: a putative mechanism of tumor regression. Am J Pathol. 1994;144:480-485.
16. Di Felice V, Lauricella M, Giuliano M, Emanuele S, Vento R, Tesoriere G. The apoptotic effects of cisplatin and carboplatin in retinoblastoma Y79 cells. Int J Oncol. 1998;13:225-232.
17. Zhang M, Stevens G, Madigan MC. In vitro effects of radiation on human retinoblastoma cells. Int J Cancer. 2001;96(suppl):7-14.
18. Bursch W, Kleine L, Tenniswood M. The biochemistry of cell death by apoptosis. Biochem Cell Biol. 1990;68:1071-1074.
19. Murray TG, Roth DB, O'Brien JM, et al. Local carboplatin and radiation therapy in the treatment of murine transgenic retinoblastoma. Arch Ophthalmol. 1996;114:1385-1389.
20. Jockovich ME, Murray TG, Escalona-Benz E, Hernandez E, Feuer W. Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice. Invest Ophthalmol Vis Sci. 2006;47:1264-1268.
21. Windle JJ, Albert DM, O'Brien JM, et al. Retinoblastoma in transgenic mice. Nature. 1990;343:665-669.
22. Jockovich ME, Bajenaru ML, Pina Y, et al. Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LHBE-TATAG mouse model. Invest Ophthalmol Vis Sci. 2007;48:2476-2482.
23. Escalona-Benz E, Jockovich ME, Murray TG, et al. Combretastatin A-4 prodrug in the treatment of a murine model of retinoblastoma. Invest Ophthalmol Vis Sci. 2005;46:8-11.
24. Hayden BH, Murray TG, Scott IU, et al. Subconjunctival carboplatin in retinoblastoma: impact of tumor burden and dose schedule. Arch Ophthalmol. 2000;118:1549-1554.
25. Hayden BC, Murray TG, Cicciarelli N, et al. Hyperfractionated external beam radiation therapy in the treatment of murine transgenic retinoblastoma. Arch Ophthalmol. 2002;120:353-359.
26. Conway RM, Wheeler SM, Murray TG, Jockovich ME, O'Brien JM. Retinoblastoma: animal models. Ophthalmol Clin North Am. 2005;18:25-39, vii.
27. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-395.
28. Teicher BA. A systems approach to cancer therapy (antioncogenics + standard cytotoxics→mechanism(s) of interaction). Cancer Metastasis Rev. 1996;15:247-272.
29. Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 2001;61:5491-5498.
30. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol. 2003;13:159-167.
31. Clark AF. Mechanism of action of the angiostatic cortisene anecortave acetate. Surv Ophthalmol. 2007;52(suppl 1):S26-S34.
32. West CM, Price P. Combretastatin A4 phosphate. Anti-cancer Drugs. 2004;15:179-187.